{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:13:49Z","timestamp":1791486829773,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s11095-025-03875-7","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T16:12:29Z","timestamp":1750176749000},"page":"1199-1229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A New Analytical LC\u2013MS\/MS Method for Determination of Eight Standard Nitrosamines (NDMA, NMBA, NDEA, NEIPA, NDIPA, NMPA, NDPA, NDBA) in a Commercial Small Molecule Drug Product Capsules and its Active Pharmaeceutical Ingredient for Treatment of Fabry: A Rare Disease"],"prefix":"10.1007","volume":"42","author":[{"given":"Krishnaiah","family":"Charagondla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha S.","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyani","family":"Ginjupalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simrat","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paresh","family":"Thanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejas","family":"Tailor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavin","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroj","family":"Ramdas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"3875_CR1","unstructured":"US Food and Drug Administration. FDA Announces Voluntary Recall of Several Medicines Containing Valsartan Following Detection of an Impurity (30 August 2022). https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-announces-voluntaryrecall-several-medicines-containing-valsartan-following-detection-impurity"},{"key":"3875_CR2","unstructured":"US Food and Drug Administration. Recalls, Market Withdrawals, & Safety Alerts. Available online (30 August 2022). https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts"},{"key":"3875_CR3","unstructured":"European Medicines Agency (EMA). Lessons learnt from presence of N-nitrosamine impurities in sartan medicines (EMA\/526934\/2019). European Medicines Agency. 2020. https:\/\/www.ema.europa.eu."},{"key":"3875_CR4","doi-asserted-by":"publisher","first-page":"834124","DOI":"10.3389\/fchem.2022.834124","volume":"10","author":"X Tao","year":"2022","unstructured":"Tao X, Tian Y, Liu WH, Yao S, Yin L. Trace Level Quantification of 4-Methyl-1-Nitrosopiperazin in Rifampicin Capsules by LC-MS\/MS. Front Chem. 2022;10:834124. https:\/\/doi.org\/10.3389\/fchem.2022.834124.","journal-title":"Front Chem"},{"key":"3875_CR5","unstructured":"European medicines agency. Committee for medicinal products for human use. ICH guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk-addendum. Amsterdam: The Netherlands. 2021;31.\u00a0https:\/\/www.ema.europa.eu\/en\/ich-m7-assessment-control-dna-reactive-mutagenic-impuritiespharmaceuticals-limit-potential-carcinogenic-risk-scientific-guideline"},{"key":"3875_CR6","unstructured":"International Agency for Research on Cancer. IARC Publications Website-Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs; International Agency for Research on Cancer: Lyon, France, 1987;1: 42. https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Iarc-Monographs-Supplements\/Overall-Evaluations-Of-Carcinogenicity-An-Updating-Of-IARC-Monographs-Volumes"},{"key":"3875_CR7","unstructured":"FDA Guidance for industry: Control of NA impurities in Human drugs, Guidance for Industry.\u00a0https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/control-NA-impurities-human-drugs"},{"key":"3875_CR8","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1208\/s12249-011-9677-z","volume":"12","author":"Y Wu","year":"2011","unstructured":"Wu Y, Levons J, Narang AS, Raghavan K, Rao VM. Reactive Impurities in Excipients: Profiling, Identification and Mitigation of Drug-Excipient Incompatibility. AAPS PharmSciTech. 2011;12:1248\u201363. https:\/\/doi.org\/10.1208\/s12249-011-9677-z.","journal-title":"AAPS PharmSciTech"},{"key":"3875_CR9","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1248\/cpb.c21-00289","volume":"69","author":"H Yokoo","year":"2021","unstructured":"Yokoo H, Yamamoto E, Masada S, Uchiyama N, Tsuji G, Hakamatsuka T, et al. N Nitrosodimethylamine (NDMA) Formation from Ranitidine Impurities: Possible Root Causes of the Presence of NDMA in Ranitidine Hydrochloride. Chem Pharm Bull. 2021;69:872\u20136. https:\/\/doi.org\/10.1248\/cpb.c21-00289.","journal-title":"Chem Pharm Bull"},{"key":"3875_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/aiht-2021-72-3491","volume":"72","author":"I Sedlo","year":"2021","unstructured":"Sedlo I, Kolonic T, Tomic S. Presence of NA Impurities in Medicinal Products. Arh Hig Rada Toksikol. 2021;72:1\u20135. https:\/\/doi.org\/10.2478\/aiht-2021-72-3491.","journal-title":"Arh Hig Rada Toksikol"},{"issue":"5","key":"3875_CR11","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.xphs.2022.11.013","volume":"112","author":"S Joerg","year":"2023","unstructured":"Joerg S, Michael JB, David JP, Carolina MA, Naiffer ER, Mrunal AJ, et al. The Landscape of Potential Small and Drug Substance Related NAs in Pharmaceuticals. J Pharm Sci. 2023;112(5):1287\u2013304. https:\/\/doi.org\/10.1016\/j.xphs.2022.11.013.","journal-title":"J Pharm Sci"},{"key":"3875_CR12","unstructured":"The EDQM\u2019s response to NA contamination.\u00a0https:\/\/www.edqm.eu\/en\/n-NA-contamination-in-brief"},{"key":"3875_CR13","unstructured":"CDER (FDA) NA Impurity Acceptable Intake Limits.\u00a0https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/cder-NA-impurity-acceptable-intake-limits"},{"key":"3875_CR14","unstructured":"NA impurities, European Medicines Agency (EMA).\u00a0https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/pharmacovigilance-post-authorisation\/referral-procedures-human-medicines\/NA-impurities"},{"key":"3875_CR15","unstructured":"Health Canada. Nitrosamine impurities in medications: Guidance. Government of Canada; 2024.\u00a0https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/informationhealth-product\/drugs\/nitrosamine-impurities\/medications-guidance.html"},{"key":"3875_CR16","unstructured":"United States Pharmacopeia (USP). General chapter 1469: Nitrosamine impurities. In: USP\u2013NF. Rockville (MD): United States Pharmacopeia. https:\/\/www.uspnf.com"},{"key":"3875_CR17","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1021\/acs.jmedchem.0c02120","volume":"64","author":"SS Bharate","year":"2021","unstructured":"Bharate SS. Critical Analysis of Drug Product Recalls Due to NA Impurities. J Med Chem. 2021;64:2923\u201336. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c02120.","journal-title":"J Med Chem"},{"key":"3875_CR18","unstructured":"Pfizer (2021). Pfizer Expands Voluntary Nationwide Recall to include All Lots of CHANTIX\u00ae (Varenicline) Tablets Due to N-Nitroso Varenicline Content. https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/pfizer-expands-voluntary-nationwide-recall-include-all-lots-chantixr-varenicline-tablets-due-n."},{"key":"3875_CR19","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jpba.2018.11.010","volume":"164","author":"MK Parr","year":"2019","unstructured":"Parr MK, Joseph JF. NDMA Impurity in Valsartan and Other Pharmaceutical Products: Analytical Methods for the Determination of N-NAs. J Pharm Biomed Anal. 2019;164:536\u201349. https:\/\/doi.org\/10.1016\/j.jpba.2018.11.010.","journal-title":"J Pharm Biomed Anal"},{"key":"3875_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40543-020-00254-2","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, Xie B, Mai B, Cai Q, He R, Guo D, et al. Development of a Sensitive and Stable GC-MS\/MS Method for Simultaneous Determination of Four N-NA Genotoxic Impurities in Sartan Substances. J Anal Sci Technol. 2021;12:3. https:\/\/doi.org\/10.1186\/s40543-020-00254-2.","journal-title":"J Anal Sci Technol"},{"key":"3875_CR21","unstructured":"US Food and Drug Administration. Headspace NDMA, NDEA, NEIPA, and NDIPA Impurity Assay by GC-MS\/MS. Silver Spring, MD, USA. 2019. https:\/\/www.fda.gov\/media\/124025\/download"},{"key":"3875_CR22","unstructured":"US Food and Drug Administration (FDA). Combined Direct Injection NDMA, NDEA, NEIPA, NDIPA, and NDBA Impurity Assay by GC-MS\/MS. https:\/\/www.fda.gov\/media\/123409\/download"},{"key":"3875_CR23","unstructured":"\u00a0US Food and Drug Administration (FDA). Combined Direct Injection NDMA and NDEA Impurity Assay by GC\/MS. https:\/\/www.fda.gov\/media\/117843\/download"},{"key":"3875_CR24","doi-asserted-by":"publisher","first-page":"11048","DOI":"10.1021\/acsomega.1c00982","volume":"6","author":"W Wisut","year":"2021","unstructured":"Wisut W, Orawan S, Pawadee S, Kamonrak C, Siriwan N, Pornchai R. Headspace Gas Chromatography-Mass Spectrometry Method for the Simultaneous Determination of NAs in Losartan Active Pharmaceutical Ingredients. ACS Omega. 2021;6:11048\u201358. https:\/\/doi.org\/10.1021\/acsomega.1c00982.","journal-title":"ACS Omega"},{"key":"3875_CR25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.38212\/2224-6614.1063","volume":"28","author":"SH Chang","year":"2020","unstructured":"Chang SH, Chang CC, Wang LJ, Chen WC, Fan SY, Zang CZ, et al. A Multi-Analyte LC-MS\/MS Method for Screening and Quantification of NAs in Sartans. J Food Drug Anal. 2020;28:292\u2013301. https:\/\/doi.org\/10.38212\/2224-6614.1063.","journal-title":"J Food Drug Anal"},{"key":"3875_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1208\/s12248-020-00473-w","volume":"22","author":"J Yang","year":"2020","unstructured":"Yang J, Marzan TA, Ye W, Sommers CD, Rodriguez JD, Keire DA. A Cautionary Tale: Quantitative LC-HRMS Analytical Procedures for the Analysis of N-Nitrosodimethylamine in Metformin. AAPS J. 2020;22:89. https:\/\/doi.org\/10.1208\/s12248-020-00473-w.","journal-title":"AAPS J"},{"key":"3875_CR27","unstructured":"European Directorate for the Quality of Medicines and HealthCare. LC-MS\/MS Method for the Determination of NDEA and NMDA in Valsartan, Irbesartan and Losartan APIs and Finished Dosage Forms (30 August 2022). https:\/\/www.edqm.eu\/sites\/default\/files\/medias\/fichiers\/Sartans\/de-by-lc-ms_ls.pdf"},{"key":"3875_CR28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jpba.2019.04.049","volume":"174","author":"S Schmidtsdorff","year":"2019","unstructured":"Schmidtsdorff S, Schmidt AH. Simultaneous Detection of NAs and Other Sartan-Related Impurities in Active Pharmaceutical Ingredients by Supercritical Fluid Chromatography. J Pharm Biomed Anal. 2019;174:151\u201360. https:\/\/doi.org\/10.1016\/j.jpba.2019.04.049.","journal-title":"J Pharm Biomed Anal"},{"key":"3875_CR29","unstructured":"French National Agency for Medicines and Health Products Safety. Determination of NDMA in Valsartan Active Substances and Finished Products by HPLC\/UV (August 2022). https:\/\/www.edqm.eu\/sites\/default\/files\/omcl-method-determinationndma-valsartan-ansm-september2018.pdf"},{"key":"3875_CR30","unstructured":"Maziarz M, Rainville P. Reliable HPLC\/UV Quantification of NA Impurities in Valsartan and Ranitidine Drug (August 2022).\u00a0https:\/\/www.waters.com\/webassets\/cms\/library\/docs\/720006775en.pdf"},{"key":"3875_CR31","doi-asserted-by":"publisher","first-page":"113582","DOI":"10.1016\/J.JPBA.2020.113582","volume":"191","author":"YM Alshehri","year":"2020","unstructured":"Alshehri YM, Alghamdi TS, Aldawsari FS. HS-SPME-GC-MS as an Alternative Method for NDMA Analysis in Ranitidine Products. J Pharm Biomed Anal. 2020;191:113582. https:\/\/doi.org\/10.1016\/J.JPBA.2020.113582.","journal-title":"J Pharm Biomed Anal"},{"key":"3875_CR32","doi-asserted-by":"publisher","unstructured":"Lim HH, Oh YS, Shin HS. Determination of N-Nitrosodimethylamine and N-Nitrosomethylethylamine in Drug Substances and Products of Sartans, Metformin and Ranitidine by Precipitation and Solid Phase Extraction and Gas Chromatography\u2013Tandem Mass Spectrometry. J. Pharm. Biomed. Anal. 2020;189. https:\/\/doi.org\/10.1016\/J.JPBA.2020.113460","DOI":"10.1016\/J.JPBA.2020.113460"},{"key":"3875_CR33","unstructured":"ICH Harmonized tripartite guideline: Validation of analytical procedures: Text and methodology Q2 (R1), October 27, 1994. https:\/\/database.ich.org\/sites\/default\/files\/Q2%28R1%29%20Guideline.pdf. Accessed 18 Sept 2023"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03875-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03875-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03875-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T22:03:54Z","timestamp":1753913034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03875-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3875"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03875-7","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research received no external financial or non-financial support.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Support"}},{"value":"Krishnaiah Charagondla, Partha S. Mukherjee, Kalyani Ginjupalli, and Saroj Ramdas report relationships with Amicus Therapeutics that include employment and equity or stocks. Bing Hu, Simrat Kaur, Paresh Thanki, Tejas Tailor and Bhavin Prajapati with SGS Health Science North America-Canada.Patents and Intellectual Property. There are no patents to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Relationships"}},{"value":"There are no additional activities to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Other Activities"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}